Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Pancreatic and esophageal cancer cohorts.

被引：0
|
作者：
Ulahannan, Susanna Varkey
Johnson, Melissa Lynne
Weiss, Mia C.
Vandross, Andrae L.
Vidal-Cardenas, Sofia Luz
Syed, Mustafa
Tolcher, Anthony W.
机构：
[1] Univ Okahoma, Hlth Sci Ctr, Oklahoma City, OK USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Washington Univ, Sch Med St Louis, St Louis, MO USA
[4] NEXT Oncol, Austin, TX USA
[5] Exelixis Inc, Alameda, CA USA
[6] NEXT Oncol, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
283-237-6846-271-2644; 3282-3306-2666-3910; 283-324; 298-145-222-184-4809-5347; 283-237-267; 261-566-9263; 283-2494; 4; 2; 14; 1;
D O I：
10.1200/JCO.2024.42.3_suppl.TPS421
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：TPS421 / TPS421
页数：1
相关论文
共 32 条
  • [1] Cohort expansion from the phase 1 JEWEL-101 study investigating the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors: Metastatic castration-resistant prostate cancer cohort.
    Ulahannan, Susanna Varkey
    Johnson, Melissa Lynne
    Weiss, Mia C.
    Vandross, Andrae L.
    Vidal-Cardenas, Sofia Luz
    Syed, Mustafa
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS237 - TPS237
  • [2] Phase I study of the tissue factor-targeting antibody-drug conjugate XB002 among patients with advanced solid tumors (JEWEL-101): Design of expansion cohorts for endometrial, epithelial ovarian, and cervical cancers
    Syed, Mustafa
    Tolcher, Anthony
    Johnson, Melissa
    Weiss, Mia
    Vandross, Andrae
    Vidal-Cardenas, Sofia
    Ulahannan, Susanna
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S280 - S280
  • [3] Phase 1 study of the tissue factor-targeting antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): Design of the triple-negative and hormone receptor-positive breast cancer expansion cohorts
    Ulahannan, Susanna
    Johnson, Melissa
    Weiss, Mia
    Vandross, Andrae
    Vidal-Cardenas, Sofia
    Syed, Mustafa
    Tolcher, Anthony
    CANCER RESEARCH, 2024, 84 (09)
  • [4] A Phase 1 study of the anti-tissue factor antibody-drug conjugate XB002 in patients with advanced solid tumors (JEWEL-101): initial results from the dose-escalation stage
    Ulahannan, S.
    Johnson, M. L.
    Park, H.
    Vandross, A.
    Uttamsingh, S.
    Li, J.
    Syed, M.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S92 - S93
  • [5] Phase I expansion study of the tissue factor (TF)etargeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
    Ulahannan, S.
    Johnson, M. L.
    Weiss, M. C.
    Vandross, A.
    Vidal-Cardenas, S.
    Syed, M.
    Tolcher, A. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S1500 - S1501
  • [6] Phase 1 Study of the Tissue Factor Targeting Antibody-Drug Conjugate XBOO2 in Patients with Advanced Solid Tumors (JEWEL-101): Design of Expansion Cohorts for Squamous Cell Carcinoma of the Head and Neck
    Ulahannan, S.
    Johnson, M.
    Weiss, M.
    Vandross, A.
    Vidal-Cardenas, S.
    Syed, M.
    Tolcher, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E31 - E32
  • [7] A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors
    Tolcher, A. W.
    Calvo, E.
    Maitland, M. L.
    Gibson, B.
    Xuan, D.
    Joh, T.
    Jackson-Fischer, A.
    Damelin, M.
    Barton, J.
    Xin, X.
    Sachdev, J. C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S724 - S724
  • [8] A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events
    Schoffski, Patrick
    Concin, Nicole
    Suarez, Cristina
    Subbiah, Vivek
    Ando, Yuichi
    Ruan, Shiling
    Wagner, Joel P.
    Mansfield, Keith
    Zhu, Xu
    Origuchi, Shizuka
    DiDominick, Sarah
    Bialucha, Carl U.
    Faris, Jason E.
    Tran, Ben
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (10) : 547 - 556
  • [9] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
    Strickler, John H.
    Weekes, Colin D.
    Nemunaitis, John
    Ramanathan, Ramesh K.
    Heist, Rebecca S.
    Morgensztern, Daniel
    Angevin, Eric
    Bauer, Todd M.
    Yue, Huibin
    Motwani, Monica
    Parikh, Apurvasena
    Reilly, Edward B.
    Afar, Daniel
    Naumovski, Louie
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) : 3298 - +
  • [10] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
    Lemech, Charlotte
    Woodward, Natasha
    Chan, Nancy
    Mortimer, Joanne
    Naumovski, Louie
    Nuthalapati, Silpa
    Tong, Bo
    Jiang, Fang
    Ansell, Peter
    Ratajczak, Christine K.
    Sachdev, Jasgit
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1815 - 1825
1234